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0022-2836 © 2011 Elsevier Ltd.Open accThe tetrameric tumor suppressor p53 plays a pivotal role in the control of
the cell cycle and provides a paradigm for an emerging class of oligomeric,
multidomain proteins with structured and intrinsically disordered regions.
Many of its biophysical and functional properties have been extrapolated
from truncated variants, yet the exact structural and functional role of
certain segments of the protein is unclear. We found from NMR and X-ray
crystallography that the DNA-binding domain (DBD) of human p53,
usually defined as residues 94–292, extends beyond these domain
boundaries. Trp91, in the hinge region between the disordered proline-
rich N-terminal domain and the DBD, folds back onto the latter and has a
cation–π interaction with Arg174. These additional interactions increase the
melting temperature of the DBD by up to 2 °C and inhibit aggregation of the
p53 tetramer. They also modulate the dissociation of the p53 tetramer. The
absence of the Trp91/Arg174 packing presumably allows nonnative DBD–
DBD interactions that both nucleate aggregation and stabilize the interface.
These data have important implications for studies of multidomain proteins
in general, highlighting the fact that weak ordered–disordered domain
interactions can modulate the properties of proteins of complex structure.© 2011 Elsevier Ltd. Open access under CC BY license.Introduction
The tumor suppressor p53 plays an essential role in
the control of the cell cycle and the protection of the
genome.1,2 It functions primarily as a transcriptionresses:
ly to this work.
inding domain; nESI-
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sactivation domain;
m coherence.
ess under CC BY license.factor by binding to specific DNA response elements
as a homotetramer and integrates a multitude of
cellular signals via protein–protein interactions to
initiate the appropriate cellular response. This
functional diversity and adaptability is provided
through a complex domain structure, which com-
prises intrinsically unfolded N- and C-terminal
extensions and linker regions that flank the struc-
tured DNA-binding domain (DBD) and tetrameriza-
tion domain.3–5 The p53 tetramers consist of dimers
of dimers, with a Kd in the low nanomolar range.
6–11
We have previously shown by mass spectrometry
that a p53 construct comprising the DBD and
tetramerization domain but not the termini, p53
(94–360), exchanges its subunits relatively slowly
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Fig. 1. Domain structure of p53. The 393-aa p53
protein has an intrinsically disordered N-terminal region
comprising the TAD and a proline-rich region (PR). The
structured DBD (red) and tetramerization domain (TET)
are connected via a flexible linker. Like the N terminus,
the C-terminal region is also disordered. See the text for
further details. The hinge region between the canonical
DBD region and the PR, containing the structurally
important Trp91, is shown in detail. In addition, domain
boundaries of p53 constructs used are highlighted.
359Modulation of Stability of the p53 Tetrameron a cellular timescale,12 with important implica-
tions for its biological activity, cellular localization
and the dominant-negative effect of mutant over
wild-type p53.
A combination of NMR, small-angle X-ray scat-
tering and electron microscopy revealed that the
full-length p53 protein has an open, cross-shaped
structure with loosely coupled DBD dimers in its
DNA-free form, whereas the structure rigidifies
upon DNA binding and becomes more compact.13,14
The transactivation domain (TAD) at the N terminus
(residues 1–60) is intrinsically disordered and can be
divided into two subdomains (TAD1 and TAD2)
responsible for binding to negative regulators,
transcriptional coactivators and components of the
transcription machinery.15–18 It is followed by a
proline-rich region, which favors a polyproline II
helix structure and serves as a rigid linker to
project the TAD away from the DBD.19 A short,
poorly characterized hinge region connects this
domain to the canonical region of the DBD,
extending from residues 94–292 (Fig. 1). Crucially,
the factors contributing to thermodynamic and
kinetic stability of the tetramer, as well as the
dynamics of domain–domain interplay, particular-
ly the role of linker regions, are only poorly
characterized at the level of the full-length protein.
Previous studies on N-terminally truncated p53
constructs have generally been done on sequences
beginning at residue 94.20–22
In about 50% of human cancers, the p53 protein is
inactivated by mutation. Most p53 cancer mutations
are located in the DBD.23,24 This domain is thermo-
dynamically and kinetically unstable. Many onco-
genic mutations lower the stability of the DBD even
further as a result of structural perturbations,
causing it to rapidly unfold at body temperature
while retaining native conformation at subphysio-
logical temperature.24–28 Such temperature-sensitive
cancer mutants are potential drug targets and can, inprinciple, be reactivated by small-molecule binders
that preferentially bind to the native state, thus
preventing unfolding.29,30 It has been suggested that
aggregation of structurally destabilized p53 cancer
mutants plays an important role in tumor induction
or progression.31 Exposure of an aggregation-prone
sequence in the DBD upon unfolding not only
results in a mere loss of function but causes an
aggregation-dependent dominant-negative effect of
mutant over wild-type p53 in heterozygous cells, in
addition to impairment of wild-type activity via
formation of mixed tetramers. Moreover, this
aggregation propensity accounts for mutant p53
oncogenic gain of function via co-aggregation with
the paralogs p63 and p73, which blocks potential
p53 salvage pathways.31 A recent study on p53(94–
360) variants suggests that the unfolding of mutant
DBD is accelerated in tetrameric p53 as a result of an
increase in the local concentration of DBDs,21
although this phenomenon has not been investigat-
ed using full-length proteins yet. A key question
when studying multidomain proteins is whether the
behavior of isolated domains or combinations
thereof reflects that of the full-length protein.
Here, we used NMR to map intramolecular
interactions in various p53 domain constructs.
Subsequent X-ray crystallography revealed that
Trp91, outside the usually defined canonical region
of the DBD, folds back onto the latter and forms a
cation–π stacking interaction with the guanidinium
group of Arg174 in the DBD. Most notably, the
absence of this N-terminal extension changes the
kinetics of tetramer assembly and aggregation
properties, presumably as a result of nonnative
DBD interactions, thus providing insights into the
dynamic nature of the full-length protein. These
data highlight the importance of studying the
contribution of the individual subdomains for a
detailed description of the full-length protein.Results
NMR studies reveal interaction between the
N terminus and the DBD of p53
To map possible interactions of the p53 N
terminus with the DBD, we conducted NMR
measurements using constructs comprising the
DBD (residues 94–312) with either full N terminus
[p53(1–312), residues 1–312] or truncated N termi-
nus [p53(61–312), residues 61–312; p53(86–312),
residues 86–312] as well as the full-length p53 (see
Fig. 1). 15N,1H heteronuclear single quantum coher-
ence (HSQC) spectra of p53(1–312) and the isolated
DBD p53(94–312) overlaid well for most DBD
residues apart from significant chemical shift per-
turbations for residues His168, Val172, Arg174,
360 Modulation of Stability of the p53 TetramerCys176, Thr211, Phe212 and Arg213. The largest
chemical shift perturbation was observed for
Arg174, indicative of a significant interaction of
this residue with the N terminus (Fig. 2). All
perturbed residues cluster to a surface patch on
the DBD, which might act as a docking site for
hydrophobic/aromatic residues (Fig. 2b). Further
analysis of chemical shift perturbations observed for
DBD constructs with truncated N terminus as well
as constructs with mutated residues in key hydro-
phobic motifs in the N terminus (TAD1/TAD2)
allowed us to define N-terminal residues involved in
the interaction with the DBD. p53(1–312) variants
with mutations of evolutionary conserved hydro-
phobic residues in TAD1 (L22Q/W23S) and TAD2(a)
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Fig. 2. Mapping of p53 DBD interactions. (a) Chemical shi
Phe212 could not be traced in p53(86–312) because of the ove
marked with an asterisk). (b) Ribbon diagram of the struc
N-terminal residue Ser96 is highlighted with an orange sp
comparing the spectra of p53(94–312) and p53(1–312)/p53(86
HSQC spectra of p53(94–312) (red), p53(61–312) (blue) and p
Arg174 is labeled. (d) Surface representation of p53(94–312) sh
as in (b). The yellow stick model shows the conformation of th
structure of p53(89–293).(W53Q/F54S) exhibited very similar spectra as the
p53(1–312) variant. Apart from some local chemical
shift perturbations at the mutation sites, no signif-
icant changes were observed for DBD residues,
indicating that the highly conserved hydrophobic
motifs within TAD1 and TAD2 are not involved in
an interaction with this domain. This result was
confirmed by the spectra of p53(61–312) and p53(86–
312) with partly truncated N termini, which were
almost identical with those of p53(1–312) containing
the full N terminus. The region of the N terminus
interacting with the DBD could, therefore, be
pinpointed to residues 86–93, the hinge region
between the structured DBD and the proline-rich
region. This region contains a tryptophan (Trp91),Zn
F212
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R213
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(d)
ft perturbations in p53(86–312) compared to p53(94–312).
rlapped position of this resonance (highlighted in red and
ture of T-p53(94–312) (chain A, PDB ID 1UOL).32 The
here. Residues showing the largest perturbations when
–312) are shown as green stick models. (c) Overlay of the
53(61–312)-W91A (green); the chemical shift position of
own in the same orientation and with the same color code
e N-terminal extension, starting with Trp91, in the crystal
Table 1. X-ray data collection and refinement statistics
Data collection
Space group P21
Cell, a, b, c (Å) 51.50, 68.45, 58.89
Cell, α, β, γ (°) 90.00, 99.46, 90.00
Molecules per asymmetric unit 2
Resolution (Å)a 44.3–1.68 (1.77–1.68)
Unique reflections 46,147
Completeness (%)a 99.5 (99.4)
Multiplicitya 3.4 (3.3)
Rmerge (%)
a,b 5.7 (22.8)
〈I/σI〉
a 13.5 (4.5)
Wilson B value (Å2) 17.9
Refinement
Number of atoms
Proteinc 3181
Water 510
Zinc 2
Rcryst (%)
d 17.3
Rfree (%)
d 20.9
RMSD bonds (Å) 0.006
RMSD angles (°) 1.08
Mean B value (Å2) 20.8
Ramachandran favored (%)e 99.0
Ramachandran outliers (%)e 0.0
a Values in parentheses are for the highest-resolution shell.
b Rmerge=∑(Ih,i− 〈Ih〉)/∑Ih,i.
c Number includes alternative conformations.
d Rcryst and Rfree=∑||Fobs|−|Fcalc||/∑|Fobs|, where Rfree
was calculated over 5% of the amplitudes chosen at random and
not used in the refinement.
e Determined using MolProbity.33
361Modulation of Stability of the p53 Tetramerwhich most likely packs against the surface patch
around Arg174/Phe212 on the DBD. In agreement
with this hypothesis, chemical shift positions for key
residues (e.g., Arg174) in the core domain surface
patch in the W91A mutant of p53(61–312) were in
between the values observed for p53(61–312) and
p53(94–312), suggesting that Trp91 is a key inter-W91
R174
F212
L1 loop
L2 loop
L3 loop
Zn
W91 R174
(a) (b)
Fig. 3. Crystal structure of the extended p53 DBD. (a) Ribbo
at the N terminus to red at the C terminus. The side chains of
shown as stick models. (b) Stereo view of the N-terminal re
Selected side chains in the L2 loop region that interact with the
hydrogen-bond network involving Ser94 is highlighted with bacting residue (Fig. 2c). Arg174 in full-length p53
had the same chemical shift as in p53(1–312), p53
(61–312) and p53(86–312), indicating that the intra-
molecular interaction of the hinge region with the
patch around Arg174 is retained in tetrameric full-
length p53.
Trp91 forms a cation–π interaction with Arg174
In order to elucidate the exact nature of the
interaction detected by NMR, we solved the crystal
structure of a DBD construct comprising residues
89–293 at 1.68 Å resolution (Table 1). The crystals
belonged to space group P21 with two molecules in
the asymmetric unit. The overall structure of the
β-sandwich and the DNA-binding region, including
the zinc coordination sphere, is essentially the same
as reported for the DBD variants with a shorter N
terminus (Fig. 3a). The Cα atoms of residues 96–290
in both chains superimpose with the equivalent
atoms in the four chains in Protein Data Bank (PDB)
ID 2OCJ34 with a root-mean-square deviation
(RMSD) of 0.3–0.6 Å, which is in the range of the
RMSD when superimposing the chains within the
asymmetric unit. In both subunits of our structure
with elongated N-terminal tail, the N-terminal
residues up to Trp91 fold back onto the DBD, in
excellent agreement with the analysis of local
chemical shift perturbations by NMR in solution
(Fig. 2d). A sharp turn within residues 94–96
facilitates this folding back of the N terminus against
the L2 loop region of the DBD. The turn is stabilized
via a hydrogen-bond network involving the hy-
droxyl group of Ser94, which is within hydrogen-
bond distance of the main-chain oxygen of Thr211,
the main-chain nitrogen and oxygen of Ser96 and
a highly coordinated structural water moleculeP92
L93
S94
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S95
W91
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L93
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S96
S94
T170 T170
F212
P92
n diagram shown with a rainbow color gradient from blue
Trp91 and Arg174, which form a cation–π interaction, are
gion. Residues 91–96 are shown as yellow stick models.
N terminus are shown as gray and green stick models. The
roken lines.
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Fig. 4. Aggregation of different p53 variants at 37 °C.
Light-scattering curves at 350 nm show that p53(94–360) is
much more prone to aggregation than the isolated DBD
(residues 94–312), p53(89–360) and the full-length protein
at a protein concentration of 3 μM (monomers).
362 Modulation of Stability of the p53 Tetramer(Fig. 3b). A further hydrogen bond links the amide
nitrogen of Ser94 with the carbonyl group of Thr170.
TheCβ atomof Pro92 packs against the aromatic ring
of Phe212. Key in positioning the extreme N
terminus is a cation–π interaction of the indole ring
of Trp91 with the guanidinium group of Arg174,
which packs in an approximately coplanar manner,
the preferred geometry in protein structures.35 The
average vertical distance between the guanidinium
and the indole plane is about 3.6 Å, and the
interplane angles are 5° and 7° in chains A and B,
respectively. The orientation of the N-terminal
residues is essentially the same in both subunits.
Residues 91–99 of both chains superimpose with an
RMSD of 0.31 Å for all equivalent atoms. For the two
preceding residues, Pro89 and Ser90, no electron
densitywas observed, indicating that they are highly
flexible and do not significantly interact with the
folded region of the DBD but point away from the
structured domain.
Thermodynamic stability of the extended DBD
The thermodynamic stability of full-length p53 is
dictated by the stability of its DBD.36 We used
differential scanning fluorimetry to investigate
whether the segment around Trp91 contributes to
the thermodynamic stability of the DBD (Table 2).
The melting temperature Tm of p53(89–293) was
increased by 0.6 °C (Tm=46.4 °C) relative to that of
p53(94–312), which lacks the N-terminal extension
but contains parts of the linker region between the
DBD and the tetramerization domain. The difference
in stability was even more pronounced in tetrameric
p53 variants that differed solely in their N-terminal
extension, as p53(89–360) showed a 2 °C increase in
Tm compared to p53(94–360). These data show that
the p53 DBD is stabilized through additional in-
teractions mediated by its N-terminal extension.
Aggregation properties of p53 domain variants
We used light scattering at 350 nm to monitor the
aggregation of different p53 domain constructs at
37 °C over a time course of 16–20 h (Fig. 4). The
scatter intensity for p53(94–360) increased rapidly
and reached saturation after about 2 h . In contrast,
the scatter intensities for p53(89–360) and full-Table 2. Melting temperature of p53 variants
p53 varianta Apparent Tm (°C)
p53(94–312), wild-type DBD 45.8±0.2
p53(89–293), wild-type DBD 46.4±0.1
p53(94–360) 50.6±0.1
p53(89–360) 52.5±0.1
a The tetrameric p53 variants contained the stabilizing muta-
tions M133L/V203A/N239Y/N268D (Joerger et al.32 and Niko-
lova et al.37).length p53 increased much more slowly and did
not reach saturation within the time of the
experiment. These data show that p53(94–360) is
much more prone to aggregation than the other
constructs, having by far the shortest half-life. The
scattering curves of p53(89–360) and the full-length
protein were almost identical, suggesting that the
short segment from residues 89–94 plays an
important role in preventing accelerated aggrega-
tion of the full-length p53 tetramer.
The isolated DBD, p53(94–312), at the same
concentrations, showed a different pattern of light
scattering—the time coursewas linear in the same time
range, showing that itwas still in the growthphase and
yet reachedmuch higher intensities despite not having
proceeded to completion (Fig. 4). The higher intensity
shows that the DBD forms much larger aggregates,
which have inherently higher scattering effects than
small aggregates, than did p53(94–360).
Intramolecular and intermolecular interactions
modulate the subunit exchange of the
p53 tetramer
Nanoflow electrospray ionization mass spectrom-
etry (nESI-MS) studies showed that the p53 variant
comprising the DBD and the tetramerization do-
main, p53(94–360), exchanges its subunits relatively
slowly, with a half-life of 160 min for the exchange of
dimeric subunits at 20 °C.12 We have now used the
same protocol of mixing equal amounts of unlabeled
protein (12C–14N) and uniformly labeled protein
(13C–15N), followed by nESI-MS analysis at various
time points after mixing to measure the subunit
exchange for p53(89–360) and the full-length p53
protein at 20 °C. As with p53(94–360), only the
exchange of dimers but not monomers was
363Modulation of Stability of the p53 Tetramerobserved within the experimental timescale. Full-
length p53 exchanged its dimeric subunits with a
half-life of 45 min (Fig. 5a), which is 3.55 times faster
than the subunit exchange in p53(94–360). Hence,
the presence of the terminal regions quenches some
of the intersubunit contacts observed in p53(94–360).
Most interestingly, the half-life for exchange of p53
(89–360) subunits was the same as that of the full-
length protein (Fig. 5b). These data suggest that, by
folding back onto the DBD, the region around Trp91
buries a surface patch on the DBD that is responsible
for nonnative intersubunit contacts in p53(94–360)
that slow down subunit exchange.0
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Fig. 5. Kinetics of subunit exchange of tetrameric p53.
Equal amounts of unlabeled (“L”, 12C–14N ) and uniformly
labeled (“H”, 13C–15N ) p53 protein were mixed followed
by nESI-MS analysis of the species present at various time
points after mixing. The kinetic modeling of subunit
exchange for (a) full-length p53 and (b) p53(89–360) at
20 °C shows that they have the same exchange rate.DiscussionThe folding and assembly of individual domains
of p53 have been studied in much detail, yet
relatively little is known about how these processes
are modulated in the full-length protein. By com-
bining stability data, measurements on the subunit
exchange by nESI-MS and structural studies to map
domain–domain interactions in the full-length pro-
tein, we were able to provide new insights into the
interplay between different domains in full-length
p53 and its effect on the stability of the p53 tetramer.
Surprisingly, the subunit exchange in p53(94–360)
was significantly slower than in the full-length
protein, suggesting that there are additional, non-
native domain–domain interactions that are either
not present or attenuated in the full-length protein.
Addition of only a few residues preceding the
canonical core domain region (including Trp91)
was sufficient to prevent this phenomenon,
highlighting the intricate oligomerization properties
of human p53. Another level of complexity is added
by the recent discoveries that interactions with
accessory proteins of the S100 family38 or 14-3-3
isoforms39,40 further modulate tetramer formation
by interacting with regions within and outside the
p53 tetramerization domain. Hence, the stability of
the p53 tetramer not only is regulated by competing
intrasubunit and intersubunit contacts but also
critically depends on the biological context and the
phosphorylation state of p53.
A study of p53(94–360) variants with cancer-
associated mutations reported that tetramer forma-
tion drastically increases the propensity of oncogen-
ic p53 mutants to misfold compared to monomeric
DBD. The authors concluded that tetramerization
establishes an efficient trap for p53 misfolding by
increasing the local DBD concentration.21 Interest-
ingly, we observed a similar proximity effect when
measuring the aggregation of p53(94–360) at body
temperature, which proceeded much faster than in
the case of the isolated DBD. Yet, importantly, this
effect was quenched in tetrameric constructs with an
extended N terminus, as p53(89–360) and the full-
length protein were much less prone to aggregation.
Most likely, exposure of a surface patch in p53(94–
360), either fully or transiently buried in the full-
length protein, results in artificially high aggrega-
tion tendencies because of enhanced nonnative DBD
interactions upon tetramer formation. Our structur-
al and biophysical data suggest that folding back of
the N-terminal DBD extension around Trp91 onto
the DBD structure plays a key role in preventing
these interactions and, hence, accelerated aggrega-
tion of the p53 tetramer. As such, the increased
aggregation tendency and the slower subunit
exchange of p53(94–360) may have the same
structural basis. The importance of regulating p53
364 Modulation of Stability of the p53 Tetrameraggregation properties has been highlighted by a
recent study showing that aggregation of structur-
ally destabilized cancer mutants is responsible for
oncogenic gain of function through co-aggregation
with the p53 family members p63 and p73.31 These
data further emphasize the special structural con-
straints on complex, oligomeric signaling proteins
such as p53 to prevent malignant transformations.
They require sufficient, tightly controlled half-lives
and structural safeguards against accelerated
unfolding and aggregation. However, at the same
time, they have to retain enough structural plasticity
for both cooperative DNA binding and interactions
with their numerous partner proteins in the cell
cycle.
Our structural data argue in favor of revising the
current domain boundaries of the p53 DBD, which,
historically, has been defined to start somewhere
between residues 94 and 102 based on proteolytic
digests and crystallographic studies.22,41 The short
segment around Trp91, although not essential for
the overall structure of the DBD, contributes to the
thermodynamic stability of the DBD by folding back
against a nonnative surface patch on the canonical
DBD region. Key to this interaction is the formationR181’
R181’’’
W91
W91’’
W91 R181’
R181’’’
(a)
(b)of an energetically favorable cation–π interaction
between Trp91 and Arg174 (Fig. 3). Trp91 is strictly
conserved in mammalian p53, suggesting a similar
structural role. Its counterparts on the surface patch,
Arg174 and Phe212, are also either strictly or highly
conserved in mammalian p53. Two recent papers
report the structure of four p53 DBDs (in both cases
without Trp91) assembled on a continuous p53
response element without spacer between the two
half-sites, typical of the majority of p53 response
elements.42,43 In one of these structures, which has
two additional N-terminal residues, Leu93 is part of
the translational interface between two DBD dimers
bound to a DNA half-site,42 which is in direct
vicinity of the docking site for the N-terminal tail,
and superimposes very well with the position of the
Leu side chain in our structure. This dimer–dimer
interface depends on the nature of the response
element (i.e., the length of the spacer between half-
sites), and the pattern of sequence conservation
follows approximately that of Trp91. Superimpos-
ing our structure with an extended N terminus onto
both DNA complexes suggests that packing of
Trp91 onto Arg174 is compatible with productive
DNA binding, as it leaves a possible trajectory forW91’’
Fig. 6. Location of the additional
N-terminal DBD residues with re-
spect to the interface regions in the
p53–DNA complex. (a) Chain A of
the DBD structure with extended N
terminus was superimposed onto
each chain of the structure of four
p53 DBDs assembled onto a full
DNA response element without
spacer between the two half-sites
(PDB ID 3KZ8).43 DNA-bound mol-
ecules are shown as cartoon repre-
sentations. Residues 91–95 of the
unbound structure are shown as a
magenta stick model, suggesting
that folding back of the N-terminal
region via Trp91 is compatible with
productive DNA binding by con-
tributing to the translational DBD–
DBD interface and projecting the
proline-rich region away from the
protein–DNA interface. (b) Close-
up stereo view of the central cavity
in (a) highlighting the proximity of
Trp91 to Arg181 from an adjacent
DBD at the interface between two
DBDs bound to a DNA half-site
and the space available for the
N-terminal extension in the full-
length protein. DNA-bound DBDs
are shown as surface representa-
tions, and the N-terminal extension
is shown as a magenta stick model.
Orientation and color code are the
same as in (a).
365Modulation of Stability of the p53 Tetramerthe N terminus without perturbation of the p53–
DNA complex (Fig. 6). As such, Trp91 may play an
important role in positioning the proline-rich region.
Another interesting aspect of this model is the fact
that the indole nitrogen of Trp91 is within approx-
imately 4.5 Å of the guanidinium group of Arg181
from an adjacent subunit, which is part of the
symmetrical DBD–DBD interface (within a half-
site), raising the possibility that Trp91 contributes to
this interface via a water-mediated contact. DNA-
binding studies in vitro have shown that binding of
the full-length protein to different p53 response
element sequences exactly parallels the DNA-
binding affinities measured for p53(94–360), imply-
ing that the N-terminal extension, including Trp91,
has no significant effect on sequence-specific DBD–
DNA interaction.44
In summary, our data show that the stability of the
full-length p53 tetramer is determined through a
dynamic interplay of intermolecular and intramo-
lecular interactions. The short segment from Trp91
to Ser94 modulates the stability of the p53 tetramer
by capping the structured region of the DBD and,
thus, forms an integral part of the DBD. The altered
molecular surface of the extended DBD structure
has, for example, implications for p53 drug discov-
ery and should be taken into account when
designing generic small-molecule binders for rescu-
ing the function of temperature-sensitive p53 cancer
mutants.3 Importantly, the data highlight that
studies on truncated variants do not fully reflect
the complexity of the full-length protein, a general
problem when studying multidomain proteins,
which are highly abundant in human signaling
networks. The energetics of the additional DBD–
DBD interdomain interactions are relatively small—
a decrease in dissociation rate constant of a factor of
3.55 is equivalent to 0.75 kcal/mol of activation
energy. Similarly, the free energy of denaturation of
p53(89–360) is only 0.75 kcal/mol higher than that of
p53(94–360), calculated from the increase in Tm of
1.9 °C and data from our previous work.36 Thus,
small changes in energy can have significant effects
on such properties as subunit dissociation and
protein aggregation when these events are on a
timescale of several minutes upwards.‡www.pymol.orgMaterials and Methods
Protein expression and purification
Unless stated otherwise, the p53 constructs used
contained four stabilizing mutations (M133L/V203A/
N239Y/N268D) in the DBD.32,37 Expression and purifica-
tion of these stabilized p53 variants followed published
protocols.13 Briefly, the p53 variants were produced
in Escherichia coli BL21(DE3) as a fusion protein withN-terminal 6×His/lipoamyl domain/tobacco etch virus
protease cleavage site. The proteins were purified using
standard His-tag purification protocols, followed by
tobacco etch virus protease digestion, heparin affinity
chromatography and a final gel-filtration step. The genes
of wild-type p53(89–293) and p53(94–312) were expressed
in E. coli C41(DE3) without an N-terminal tag using a pET-
24a(+) vector, as described previously for several DBD
mutants,45,46 and the proteins were purified by cation-
exchange chromatography on a Sepharose SP column (GE
Healthcare), affinity chromatography on HiTrap Heparin
(GEHealthcare) and gel filtration on a Superdex 75 column
(GEHealthcare) as the final purification step. Expression of
15N- and 13C-labeled p53 was carried out in M9 minimal
medium supplemented with vitamins, minerals and 1 g/L
15NH4Cl and
13C D-glucose.
NMR
All two-dimensional HSQC spectra were acquired on
Bruker Avance 600- and 800-MHz spectrometers
equipped with triple-resonance TXI cryoprobes at protein
concentrations of 50–450 μM in 25 mM sodium phosphate
buffer, 150 mM NaCl, 5 mM DTT and 5% D2O (v/v).
Standard triple-resonance experiments were used to
confirm the resonance assignments in the p53(1–312)
construct. All data were processed in Topspin (Bruker,
Karlsruhe), referenced against the internal water signal
and analyzed in Sparky (Goddard and Kneller, SPARKY
3, University of California, San Francisco). The weighted
15N,1H chemical shift perturbations (in parts per million)
were calculated according to |Δδ(1H)|+|Δδ(15N)|/5
based on the observed individual chemical shift differ-
ences Δδ1H and Δδ15N (in parts per million) utilizing in-
house perl scripts with drift correction (T. J. Rutherford).
X-ray crystallography
Crystals of the DBD with extended N terminus
(residues 89–293) were grown by sitting-drop vapor
diffusion at 17 °C. One microliter of protein solution
[5.4 mg/mL in 25 mM sodium phosphate (pH 7.2),
220 mMNaCl and 5 mMDTT] and 1 μL reservoir solution
[100 mM 2-[bis(2-hydroxyethyl)amino]-2-(hydroxy-
methyl)propane-1,3-diol (pH 5.5), 23% polyethylene gly-
col 3350 and 200 mM ammonium sulfate] were mixed
above a reservoir of 85 μL. Crystals grew within a few
days. They were soaked in mother liquor supplemented
with 10% glycerol and flash frozen in liquid nitrogen. An
X-ray data set was collected at the Diamond Light Source
(beamline I04) and was processed with MOSFLM47 and
SCALA.48 The structure was solved by molecular replace-
ment with Phaser49 using chain A of PDB ID 1UOL32 as a
search model. Subsequent structure refinement was
performed using PHENIX,50 and manual model building,
with Coot.51 Data collection and refinement statistics are
summarized in Table 1. Structural figures were prepared
with PyMOL‡.
366 Modulation of Stability of the p53 TetramerSubunit exchange and mass spectrometry
In a typical subunit exchange reaction, equal amounts of
[12C–14N]p53 and [13C–15N]p53 ([p53]total=10 μM, in
tetramers) in either 250 mM (full-length p53) or 500 mM
[p53(89–360)] ammonium acetate, pH 6.9, were mixed and
incubated at 20 °C. At different time points after mixing,
samples were taken, and nanoflow electrospray ionization
mass spectra were recorded on either a Q ToF II or a Synapt
HDMS system (Waters Corp., Milford, MA) optimized for
the transmission of noncovalent complexes.52 The follow-
ing instrument parameters were used: (i) Q ToF II: capillary
voltage, 1.5 kV; sample cone, 100 V; transfer extractor cone,
40 V; accelerating voltage into the collision cell, 10 V; ion
transfer stage pressure, 3×10−3 mbar; and ToF analyzer
pressure, 1.34×10−6 mbar. (ii) Synapt HDMS: capillary
voltage, 1.0–1.5 kV; sample cone, 50 V; cone gas, off; trap
and transfer collision voltage, 50 V; ion transfer stage
pressure, 4.40 mbar; trap pressure, 4.95×10−2 mbar; ion
mobility cell pressure, 4.34×10−1 mbar; and ToF analyzer
pressure, 1.17×10−6 mbar. Calibration, data processing,
spectra simulation andkineticmodelingwere performed as
described previously.12
Differential scanning fluorimetry
Thermal unfolding of p53 was followed by monitoring
the binding of the dye SYPRO Orange (diluted 5000-fold;
Invitrogen) using a Rotor-Gene 6000 real-time PCR
thermocycler (Qiagen) with a scan rate of 270 °C/h in
25 mM sodium phosphate (pH 7.2), 150 mM NaCl and
5 mM DTT. The sample size was 20 μL, and the protein
concentration was 10 μM (monomers). Experiments were
carried out in quadruplicate. Data analysis was performed
with the software supplied by the manufacturer.
Light-scattering measurements
Aggregation of different p53 variants at 37 °C was
measured by light scattering in a FluoroMax-3 spectroflu-
orometer equipped with a thermostatted cell holder at an
excitation and emissionwavelength of 350nm. Spectrawere
recorded over a time course of 16–20 h . The slit widths for
excitation and emission were 0.5 and 1.0 nm, respectively.
The protein concentration was 3 μM (monomers) in 25 mM
sodium phosphate (pH 7.2), 150 mMNaCl and 5 mMDTT.
Accession numbers
The atomic coordinates and structure factor amplitudes
for the extended p53 DBD have been deposited in the
PDB§ (PDB ID 2XWR).Acknowledgements
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